Answers are grounded in this paper and cite their sources.
Background and aims: Treatment of hepatitis C has become revolutionised with the availability of newer direct acting antiviral (DAA) in last two years. In India, Sofosbuvir was the only available DAA till December 2015.
No takes yet. Share an insight, caveat, or question.
Ruchir Patel (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: